Literature DB >> 25636761

Evaluating tumor response of non-small cell lung cancer patients with ¹⁸F-fludeoxyglucose positron emission tomography: potential for treatment individualization.

Iuliana Toma-Dasu1, Johan Uhrdin2, Marta Lazzeroni3, Sara Carvalho4, Wouter van Elmpt4, Philippe Lambin4, Alexandru Dasu5.   

Abstract

OBJECTIVE: To assess early tumor responsiveness and the corresponding effective radiosensitivity for individual patients with non-small cell lung cancer (NSCLC) based on 2 successive (18)F-fludeoxyglucose positron emission tomography (FDG-PET) scans. METHODS AND MATERIALS: Twenty-six NSCLC patients treated in Maastricht were included in the study. Fifteen patients underwent sequential chemoradiation therapy, and 11 patients received concomitant chemoradiation therapy. All patients were imaged with FDG before the start and during the second week of radiation therapy. The sequential images were analyzed in relation to the dose delivered until the second image. An operational quantity, effective radiosensitivity, αeff, was determined at the voxel level. Correlations were sought between the average αeff or the fraction of negative αeff values and the overall survival at 2 years. Separate analyses were performed for the primary gross target volume (GTV), the lymph node GTV, and the clinical target volumes (CTVs).
RESULTS: Patients receiving sequential treatment could be divided into responders and nonresponders, using a threshold for the average αeff of 0.003 Gy(-1) in the primary GTV, with a sensitivity of 75% and a specificity of 100% (P<.0001). Choosing the fraction of negative αeff as a criterion, the threshold 0.3 also had a sensitivity of 75% and a specificity of 100% (P<.0001). Good prognostic potential was maintained for patients receiving concurrent chemotherapy. For lymph node GTV, the correlation had low statistical significance. A cross-validation analysis confirmed the potential of the method.
CONCLUSIONS: Evaluation of the early response in NSCLC patients showed that it is feasible to determine a threshold value for effective radiosensitivity corresponding to good response. It also showed that a threshold value for the fraction of negative αeff could also be correlated with poor response. The proposed method, therefore, has potential to identify candidates for more aggressive strategies to increase the rate of local control and also avoid exposing to unnecessary aggressive therapies the majority of patients responding to standard treatment.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25636761     DOI: 10.1016/j.ijrobp.2014.10.012

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  11 in total

1.  PET/CT-Based Response Evaluation in Cancer-a Systematic Review of Design Issues.

Authors:  Oke Gerke; Karen Ehlers; Edith Motschall; Poul Flemming Høilund-Carlsen; Werner Vach
Journal:  Mol Imaging Biol       Date:  2020-02       Impact factor: 3.488

2.  A geometric atlas to predict lung tumor shrinkage for radiotherapy treatment planning.

Authors:  Pengpeng Zhang; Andreas Rimner; Ellen Yorke; Yu-Chi Hu; Licheng Kuo; Aditya Apte; Natalie Lockney; Andrew Jackson; Gig Mageras; Joseph O Deasy
Journal:  Phys Med Biol       Date:  2017-01-10       Impact factor: 3.609

3.  Regional Lymph Node Uptake of [(18)F]Fluorodeoxyglucose After Definitive Chemoradiation Therapy Predicts Local-Regional Failure of Locally Advanced Non-Small Cell Lung Cancer: Results of ACRIN 6668/RTOG 0235.

Authors:  Stephanie Markovina; Fenghai Duan; Bradley S Snyder; Barry A Siegel; Mitchell Machtay; Jeffrey D Bradley
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-11-01       Impact factor: 7.038

4.  Effects of Tracer Uptake Time in Non-Small Cell Lung Cancer 18F-FDG PET Radiomics.

Authors:  Guilherme D Kolinger; David Vállez García; Gerbrand Maria Kramer; Virginie Frings; Gerben J C Zwezerijnen; Egbert F Smit; Adrianus Johannes de Langen; Irène Buvat; Ronald Boellaard
Journal:  J Nucl Med       Date:  2021-12-21       Impact factor: 11.082

5.  Robust Intratumor Partitioning to Identify High-Risk Subregions in Lung Cancer: A Pilot Study.

Authors:  Jia Wu; Michael F Gensheimer; Xinzhe Dong; Daniel L Rubin; Sandy Napel; Maximilian Diehn; Billy W Loo; Ruijiang Li
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-03-24       Impact factor: 7.038

6.  Repeatability of Radiomic Features in Non-Small-Cell Lung Cancer [(18)F]FDG-PET/CT Studies: Impact of Reconstruction and Delineation.

Authors:  Floris H P van Velden; Gerbrand M Kramer; Virginie Frings; Ida A Nissen; Emma R Mulder; Adrianus J de Langen; Otto S Hoekstra; Egbert F Smit; Ronald Boellaard
Journal:  Mol Imaging Biol       Date:  2016-10       Impact factor: 3.488

7.  The evaluation of a hybrid biomechanical deformable registration method on a multistage physical phantom with reproducible deformation.

Authors:  An Qin; Dan Ionascu; Jian Liang; Xiao Han; Nicolette O'Connell; Di Yan
Journal:  Radiat Oncol       Date:  2018-12-04       Impact factor: 3.481

8.  Repeatability of [18F]FDG PET/CT total metabolic active tumour volume and total tumour burden in NSCLC patients.

Authors:  Guilherme D Kolinger; David Vállez García; Gerbrand M Kramer; Virginie Frings; Egbert F Smit; Adrianus J de Langen; Rudi A J O Dierckx; Otto S Hoekstra; Ronald Boellaard
Journal:  EJNMMI Res       Date:  2019-02-07       Impact factor: 3.138

9.  Evolution of the hypoxic compartment on sequential oxygen partial pressure maps during radiochemotherapy in advanced head and neck cancer.

Authors:  Marta Lazzeroni; Ana Ureba; Nicole Wiedenmann; Nils H Nicolay; Michael Mix; Benedikt Thomann; Dimos Baltas; Iuliana Toma-Dasu; Anca L Grosu
Journal:  Phys Imaging Radiat Oncol       Date:  2021-02-11

10.  The expression of miRNA-216b is negatively correlated with 18F-FDG uptake in non-small cell lung cancer.

Authors:  Mingfei Zuo; Lan Yao; Lijuan Wen; Jianfei Shen; Na Zhang; Tian Bai; Qicheng Huang
Journal:  World J Surg Oncol       Date:  2021-09-01       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.